Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study.

Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study.

PURPOSE:As the major toxicity induced by pemetrexed plus carboplatin is severe hematologic toxicities, the aim of this study was to determine the risk factors for severe hematologic toxicities in lung cancer patients. METHODS:We retrospectively investigated data from lung cancer patients who had rec...

Full description

Bibliographic Details
Main Authors:	Hitoshi Kawazoe, Akiko Yano, Yuri Ishida, Kenshi Takechi, Hitoshi Katayama, Ryoji Ito, Yoshihiro Yakushijin, Toshihide Moriguchi, Mamoru Tanaka, Akihiro Tanaka, Hiroaki Araki
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5291448?pdf=render

Similar Items

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
by: Sae Wada, et al.
Published: (2012-01-01)

Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma
by: Songliang ZHANG, et al.
Published: (2015-06-01)

Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report
by: Sato Takashi, et al.
Published: (2012-08-01)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
by: Toshinobu Hayashi, et al.
Published: (2021-01-01)

Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries.
by: Binu eMalhotra, et al.
Published: (2015-01-01)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
by: Nicole F. Laslett, et al.
Published: (2018-07-01)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
by: Andrés Felipe Cardona, et al.
Published: (2016-01-01)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
by: Schuette W, et al.
Published: (2017-11-01)

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
by: Meng Zhao-Ting, et al.
Published: (2010-04-01)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
by: Vamsidhar Velcheti, et al.
Published: (2021-04-01)

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma
by: Treat Joseph, et al.
Published: (2011-02-01)

Pemetrexed Combined with Cisplatin or Carboplatin Regimen in the Treatment of Advanced Recurrent or Metastasis Non-small Cell Lung Cancer: Analysis of 63 Cases
by: Wei WANG, et al.
Published: (2011-01-01)

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report
by: Keita Kawakado, et al.
Published: (2021-09-01)

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients
by: Afandi Charles, et al.
Published: (2016-11-01)

Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age
by: Shinji Hasebe, et al.
Published: (2018-06-01)

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
by: Zhonghan Zhang, et al.
Published: (2019-12-01)

Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan
by: Yuichi Tasaka, et al.
Published: (2018-12-01)

Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer
by: Nobuyuki Yamamoto, et al.
Published: (2020-07-01)

Pemetrexed‐induced pseudocellulitis
by: Yang Lo, et al.
Published: (2020-11-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

A New Approach for Evaluating Renal Function and Its Practical Application
by: Akihiro Tanaka, et al.
Published: (2007-01-01)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
by: Abdel Kader Y, et al.
Published: (2013-07-01)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
by: Isabelle Monnet, et al.
Published: (2021-04-01)

Involvement of stimulation of α7 nicotinic acetylcholine receptors in the suppressive effect of tropisetron on dextran sulfate sodium-induced colitis in mice
by: Yuichi Tasaka, et al.
Published: (2015-03-01)

Oral Mucosal Adhesive Films Containing Royal Jelly Accelerate Recovery From 5-Fluorouracil–Induced Oral Mucositis
by: Shinichi Watanabe, et al.
Published: (2013-01-01)

Molecular determinants of response to pemetrexed
by: Margetts, Jane
Published: (2011)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

A new member of fossil balaenid (Mysticeti, Cetacea) from the early Pliocene of Hokkaido, Japan
by: Yoshihiro Tanaka, et al.
Published: (2020-04-01)

A Note on Generalized Fractional Integral Operators on Generalized Morrey Spaces
by: Sugano Satoko, et al.
Published: (2009-01-01)

A Note on Generalized Fractional Integral Operators on Generalized Morrey Spaces
by: Yoshihiro Sawano, et al.
Published: (2009-01-01)

Limiting case of the boundedness of fractional integral operators on nonhomogeneous space
by: Sobukawa Takuya, et al.
Published: (2006-01-01)

Effect of lateral confining reinforcement on the ductile behaviour of reinforced concrete columns
by: Tanaka, Hitoshi
Published: (2008)

Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials
by: Senri Yamamoto, et al.
Published: (2021-07-01)

Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E
by: Rajini Katipamula, et al.
Published: (2008-01-01)

Nephrotoxicity in a patient treated with pemetrexed
by: Y Zajjari, et al.
Published: (2017-01-01)

New Polymorphic Forms of Pemetrexed Diacid and Their Use for the Preparation of Pharmaceutically Pure Amorphous and Hemipentahydrate Forms of Pemetrexed Disodium
by: Olga Michalak, et al.
Published: (2015-07-01)

Carboplatin-Induced Hypersensitivity Reaction
by: Evangelos Potolidis, et al.
Published: (2012-03-01)

COMPARISON BETWEEN GEMCITABINE-CARBOPLATIN AND COMBINATION OF GEMCITABINE-CARBOPLATIN AND CELECOXIB IN UROTHELIAL CARCINOMA CELL APOPTOSIS
by: Widya Sakti Pratama, et al.
Published: (2019-01-01)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
by: Yiyang Qin, et al.
Published: (2017-12-01)